Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by bluebird bio, Inc. < Previous 1 2 Next > bluebird bio Announces Receipt of Expected Notices from Nasdaq August 23, 2024 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance August 14, 2024 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Announces Second Quarter 2024 Results Call Date August 12, 2024 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) August 02, 2024 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4) July 03, 2024 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Appoints O. James Sterling as Chief Financial Officer May 29, 2024 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance May 09, 2024 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events May 06, 2024 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy May 06, 2024 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Announces Receipt of Expected Notice from Nasdaq April 26, 2024 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 11, 2024 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance March 26, 2024 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call March 25, 2024 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital March 18, 2024 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy March 11, 2024 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook January 08, 2024 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock December 19, 2023 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio, Inc. Announces Proposed Public Offering of Common Stock December 18, 2023 From bluebird bio, Inc. Via Business Wire Tickers BLUE Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels December 10, 2023 From bluebird bio, Inc. Via Business Wire Tickers BLUE Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events December 09, 2023 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events December 08, 2023 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events December 08, 2023 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress November 07, 2023 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition November 02, 2023 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million October 30, 2023 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio to Host Third Quarter 2023 Financial Results Conference Call October 24, 2023 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Announces September Investor Events September 05, 2023 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease August 16, 2023 From bluebird bio, Inc. Via Business Wire Tickers BLUE bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress August 08, 2023 From bluebird bio, Inc. Via Business Wire Tickers BLUE < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.